THERAPY DOSSIER · th-128f24999075

Dipotassium glycyrrhizate (DPG), a salt of glycyrrhizin

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: In trials, not approved
ChEMBL record: CHEMBL1923952 ↗
ChEMBL max phase: -1 / 4 (development scale, not regulatory approval)
Synonyms: Dipotassium glycyrrhizate; Dipotassium glycyrrhizinate; Glycyrrhizic acid dipotassium; Glycyrrhizinate dipotassium
Note: Not recorded

Clinical trials 5

1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

NCT07236567 ↗Injury indicationNAnot yet recruiting

Grape Seed Extract, Glycyrrhizin vs Triple Antibiotic Paste as Intra Canal Medication in Revascularization of Necrotic Permanent Immature Teeth

Traumatic Teeth · Necrotic Teeth

Enrolment: 45 · Results not recorded

NCT05916911 ↗PHASE4unknown

GLIZIGEN (glycyrrhizic acid) Oral Solution and Vaginal Gel in Patients With CIN-1 Caused by High-risk HPV

Papilloma Viral Infection · CIN1 · LSIL

Enrolment: 120 · Results not recorded

NCT06453304 ↗PHASE2/PHASE3unknown

Clinical Investigation of the Effectiveness of Glycyrrhizin as Intracanal Medication in Root Canal Disinfection

Intracanal Medication

Enrolment: 36 · Results not recorded

NCT07616271 ↗PHASE2/PHASE3not yet recruiting

Oral Diammonium Glycyrrhizinate for Attenuating Toxicity and Enhancing Efficacy of CAR-T Cell Therapy

Large B-cell Lymphoma Receiving CAR-T Cell Therapy

Enrolment: 21 · Results not recorded

NCT01643447 ↗NAcompleted

Ulinastatin's Drug Protection in HCC Postoperative Hepatic Failure (comparator: diammonium glycyrrhizinate)

Hepatocellular Carcinoma

Enrolment: 200 · Results not recorded

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31105713 ↗2019Reported benefit

Dipotassium Glycyrrhizate Improves Intestinal Mucosal Healing by Modulating Extracellular Matrix Remodeling Genes and Restoring Epithelial Barrier Functions.

MouseChemical/toxinC57BL/6femalen = Acute colitis: 8 mice per group across three groups; PCR ar…oral gavage8 mg/kg/day diluted in phosphate buffered saline; 300 micro…Acute experiment: given concurrently with the 7-day DSS exposure. Recovery expe…

Model: Dextran sodium sulfate colitis. Acute model: 3% DSS (36,000-50,000 Da) in drinking water for 7 days. Recovery model: 3% DSS for 5 days followed by 9 days of regular water or treatment

DPG downregulated 20 of 24 DSS-induced mucosal healing genes in acute colitis and accelerated recovery (full recovery at 72 h versus 144 h for vehicle; at 24 h weight 95 +/- 2 versus 87 +/- 1.1 per cent, colon length 7.5 +/- 0.43 versus 5.7 +/- 0.33 cm, histological score 0.9 +/- 0.2 versus 1.9 +/-…

Extraction: extract · Supplied extraction confidence: 0.95. Machine-extracted fields require source verification.

Loading the evidence…